Research Article| Volume 51, ISSUE 4, P507-513, March 2015

Download started.


Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency

Published:January 07, 2015DOI:



      The aim of this retrospective, registry-based study was to analyse treatment outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib and renal insufficiency (RI).


      The cohort included 790 patients treated with sunitinib between 2006 and 2013. At the start of sunitinib therapy 22, 234, and 534 patients had severe (glomerular filtration rate [GFR] <30 ml/min/1.73 m2), moderate (GFR 30–60 ml/min/1.73 m2) or mild RI/normal renal function (GFR >60 ml/min/1.73 m2), respectively.


      For the three groups defined above, median progression-free survival (PFS) (95% confidence interval [CI]) was 5.3 months (0.1–18.5), 8.1 months (6.2–9.9) and 11.3 months (9.4–13.2) (p = 0.244), and median overall survival (OS) was 26.3 months (1.2–51.4), 21.2 months (13.2–29.1) and 26.3 months (22.6–29.9) (p = 0.443), respectively. The disease control rates were 45.5%, 56.4% and 59.2%, respectively (p = 0.374). No unexpected toxicity was reported in the patients with RI, but the treatment was more frequently discontinued because of adverse events and the duration of therapy was significantly shorter in these patients (p = 0.007).


      Duration of first-line targeted treatment for mRCC was significantly shorter for patients with RI, and may have translated into a trend to shorter PFS. These results highlight the need for optimal management of side-effects in patients with mRCC and RI.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. IARC CancerBase no. 11 (online). International Agency for Research on Cancer, Lyon, France, 2012. Available from URL: [accessed on 30.07.14].

        • Poprach A.
        • Bortlicek Z.
        • Buchler T.
        • et al.
        Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database.
        Med Oncol. 2012; 29: 3314-3320
        • Buchler T.
        • Klapka R.
        • Melichar B.
        • et al.
        Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry.
        Ann Oncol. 2012; 23: 395-401
        • Motzer R.J.
        • Hutson T.E.
        • Tomczak P.
        • et al.
        Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
        J Clin Oncol. 2009; 27: 3584-3590
        • Khan G.
        • Golshayan A.
        • Elson P.
        • et al.
        Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.
        Ann Oncol. 2010; 21: 1618-1622
        • Coresh J.
        • Selvin E.
        • Stevens L.A.
        • et al.
        Prevalence of chronic kidney disease in the United States.
        JAMA. 2007; 298: 2038-2047
      2. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.
        Am J Kidney Dis. 2002; 2: S1-S266
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
      3. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. May 28, 2009, U.S Department of Health and Human Services; National Institutes of Health; National Cancer Institute. Available from URL: [accessed on 10.08.14].

        • Hudes G.
        • Carducci M.
        • Tomczak P.
        • et al.
        Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
        N Engl J Med. 2007; 356: 2271-2281
      4. Billemont B, Thibault F, Ropert S, et al. Association between acute severe renal toxicity (ASRT) and survival in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving sunitinib. In: Genitourinary Cancer Symposium; Orlando, 2009 (abstract 307). Available from URL: [accessed on 10.08.14].

        • Zhu X.
        • Stergiopoulos K.
        • Wu S.
        Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.
        Acta Oncol. 2009; 48: 9-17
        • Kim K.H.
        • Kim H.Y.
        • Kim H.R.
        • et al.
        Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
        Eur J Cancer. 2014; 50: 746-752
        • Josephs D.
        • Hutson T.E.
        • Cowey C.L.
        • et al.
        Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
        BJU Int. 2011; 108: 1279-1283
        • Faivre S.
        • Delbaldo C.
        • Vera K.
        • et al.
        Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
        J Clin Oncol. 2006; 24: 25-35